- Dangerous Drugs / Products
- Military Injuries
- Transvaginal Mesh
What is Nephrogenic Systemic Fibrosis (NSF)?
Nephrogenic Systemic Fibrosis (NSF) is a rare but potentially fatal disease that causes thickening of the skin, tissues and organs. Those who are affected by this disease may experience limited mobility and may become wheelchair bound. In the most severe cases, a person may die from complications of NSF.
If you or a family member have an impaired kidney and underwent an MRI scan that used a gadolinium-agent, you may be at risk for NSF. The gadolinium-dye lawyers at Glen Lerner Injury Attorneys are now reviewing lawsuit claims against the makers of gadolinium-based contrast agents (GBCA) on behalf of clients injured by gadolinium. Schedule a free case evaluation today by calling 1 (800) GET-GLEN today.
A doctor will request a magnetic resonance imaging (MRI) scan to obtain a picture of a patient’s brain, spine or other internal organ. The use of a gadolinium-dye injection prior to an MRI is to help the contrast agent work through a patient’s blood stream and basically highlight abnormal tissues on an image scan to assist in diagnosing ailments.
The first GBCA was approved for use in MRIs in 1988. Currently there are six approved variations of this agent in use:
In 2006, the FDA issued public health advisories that warned doctors, manufacturers and the general public about a link between GBCA enhanced MRI scans and patients that later developed Nephrogenic Systemic Fibrosis. Those at an even higher risk of developing NSF after a GBCA injection were patients who suffer from impaired kidneys as their bodies are not able to eliminate the agent properly, leading to a toxic reaction.
In 2010, the American College of Radiology issued an advisory stating that OptiMARK, Magnevist, and Omniscan were the GBCAs most often linked to an increased risk of patients developing NSF. To help reduce the risk of NSF among patients, the FDA suggests that only the minimum manufacturer recommended dosage be used during an MRI. The FDA has not approved GBCA use during an MRA.
The gadolinium attorneys at Glen Lerner Injury Attorneys are now reviewing claims against the makers of gadolinium. These gadolinium lawsuits allege that the manufacturers did not adequately test their products for severe side effects to include the risk of developing NSF.
Schedule a free initial consultation with a GBCA class action lawyer at Glen Lerner Injury Attorneys to help determine if you may be entitled to compensation for injuries suffered as a result of a GBCA. Call 1 (800) GET-GLEN today.
Contact a doctor immediately if you or a loved one experiences any of the following health conditions after receiving a gadolinium-based contrast agent (GBCA). These NSF symptoms may appear a few days after a gadolinium-dye injection or months later:
Contact a Glen Lerner gadolinium-agent attorney as soon as possible if you or a loved one is diagnosed with NSF in order to ensure that your legal rights are protected. One of our experienced gadolinium class action lawsuit attorneys will answer your questions and help you determine if you or a loved one may be entitled to compensation for any injuries suffered as a result of a GBCA. Call 1 (800) GET-GLEN today to schedule a no obligation, free consultation.
Glen Lerner Injury Attorneys is one of the largest personal injury law firms in the country with nationwide offices located in Nevada, Arizona, Minnesota, Louisiana, Illinois and Florida. Our attorneys are experienced at going up against large corporate pharmaceutical giants and are able to handle personal injury cases and class action medical and product liability class action claims.
We have settled or tried to verdict over 75 cases in excess of a million dollars in the last decade alone. Don’t wait! Call 1 (800) GET-GLEN to schedule a free consultation with one of our gadolinium-based contrast agent attorneys today. We are ready to fight for you!
Copyright © 2013 1800getglen.com, all rights reserved.
Some work may be performed by or referred to other attorneys. Initial case consultations and evaluations are free to clients. The charging of a fee is contingent on outcome or the fee will be a percentage of the recovery. Client may have to pay the opposing party’s attorney fees and costs in the event of a loss.
The information on this web site, its associated comments, answers, forms, documents, emails or other communication channels should not be construed as legal advice. Nor does viewing or interacting with them create or constitute an attorney-client relationship. If you seek legal advice, you should speak directly with an attorney to discuss your current circumstances.